Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The FDA expands Vizamyl's use for Alzheimer diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.

FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis

Skyhawk Therapeutics initiates FALCON-HD trial for SKY-0515, a promising treatment for Huntington disease, aiming to modify disease progression.

Patient Dosing Underway in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington Disease

Videos

The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD

Fremanezumab shows significant long-term effectiveness in reducing migraine frequency and severity, enhancing patient outcomes in chronic and episodic cases.

Phase 4 PEARL Study Confirms Long-Term Effectiveness of Fremanezumab in Preventing Chronic, Episodic Migraine

Associate professor of neurology at Emory University and co-director of the Emory ALS Center.

Experts in ALS care and research shared their optimism about emerging treatments, aiming to deepen scientific understanding, and the potential role of advocacy in accelerating progress. [WATCH TIME: 4 minutes]

Clinicians Express Growing Optimism in ALS Research and Treatment Advancements

Chief Scientific Officer, Dravet Syndrome Foundation

Veronica Hood, PhD, chief scientific officer at the Dravet Syndrome Foundation, discussed the evolving care landscape of Dravet syndrome, highlighting breakthroughs in precision medicine and promising new therapies for patients.

The Changing Landscape of Dravet Syndrome 

Experts discussed the ongoing importance of awareness, funding, and early diagnosis in amyotrophic lateral sclerosis, welcoming the return of the well-known Ice Bucket Challenge. [WATCH TIME: 5 minutes]

Reviving ALS Awareness Campaigns to Reaffirm Support for the Patient Community

Clinicians reflected on the unique, patient-centered format of the ALS Nexus conference and its potential role in accelerating ALS research and promoting care collaboration. [WATCH TIME: 4 minutes]

Highlighting the Collaborative and Inclusive Spirit of the ALS Nexus Conference

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Slideshows

What neuropsychiatric conditions are relatives of people with ALS at risk for? Are other genes involved besides C9orf72?

Clinical

Neuropsychiatric Disorders and Amyotrophic Lateral Sclerosis

Neuropsychiatric Disorders and Amyotrophic Lateral Sclerosis

Newsletter